Janssen Admits On Their Website Elmiron Causes Pigmentary Maculopathy And Has Other Serious Side Effects

Science day may have ended Janssen Pharmaceutical's hopes of defending their anti interstitial cystitis drug

Monday, November 8, 2021 - By all recent accounts, more than 550 Elmiron eyes problem lawsuits have been filed and consolidated in the U.S. District Court in New Jersey with Judge Brian R. Martinotti presiding. On September 30, 2021, the judge held a virtual science day over the internet and interviewed scientific experts from both sides. The purpose of Science day was to help the judge narrow down the list of witnesses either side may call to only the most credible. MDL is an excellent way to save time and taxpayer money by not replicating administrative court proceedings and the discovery process hundreds or thousands of times in courtrooms across America. Consolidating cases in MDL is preferred to eliminate expert witnesses that may exaggerate their findings and inflame the juror's emotions rather than focusing on hard scientific facts. Judge Martinotti will select only two or three experts from each side to testify during trials that could begin as early as January 2023.

While study after study continues to support that taking Elmiron, the only FDA-approved medicine to treat interstitial cystitis, the defense only recently, in June 2020, admitted that the long-term use of Elmiron causes a form of eyesight damage called pigmentary maculopathy. One study is has found that one in four patients that take Elmiron will one day experience night vision damage. Another study says that the more Elmiron a patient takes, the greater the vision damage will be. Yet another study says that a patient's vision damage will continue to worsen even if taking Elmiron is discontinued, making large punitive damages likely. Pigmentary maculopathy is a form of night blindness that causes the victim to be unable to see at night and also unable to read in less than optimal lighting conditions. For more than twenty years maculopathy was explained away as being natural and "age-related."

Janssen Pharmaceuticals and Johnson and Johnson have enjoyed a monopoly on selling Elmiron for over 20 years. It was not until June of 2020 that the company updated its product warnings on Elmiron to include vision damage. Janssen Pharmaceuticals and Johnson and Johnson tell users Elmiron vision loss side effects have been reported by users. "Serious side effects have been reported with the use of Elmiron, including changes in the retina of the eye (pigmentary maculopathy). Taking Elmiron may be associated with pigment changes in the retina of the eye that may continue even after stopping treatment with Elmiron. Tell your healthcare provider including your eye doctor right away if you have any vision changes including difficulty reading, your vision takes longer to adjust to low or reduced light or blurred vision." The companies advise that prospective Elmiron patients get eyesight examinations regularly focusing on detecting changes in the retina for the entire time they take Elmiron. Given the companys' admissions that their drug causes permanent, irreversible, vision damage, and that they hid that fact from doctors and users for two decades, it would be difficult to imagine what the defense strategy would be.

More Recent Elmiron Eye Lawsuit News:

Lawyers for Elmiron Eye Lawsuits

Attorneys handling Elmiron Eye lawsuits for leukemia, non-Hodgkin lymphoma, and multiple myeloma offer free, no-obligation case review for individuals and families who believe they may have grounds to file a Elmiron Eye lawsuit. Working on a contingency basis, these attorneys are committed to never charging legal fees unless they win compensation in your Elmiron Eye lawsuit. The product liability litigators handling Roundup claims at OnderLaw have a strong track record of success in representing families harmed by dangerous drugs and consumer products.